Bio-Techne Corp.
(NASDAQ : TECH)

( )
TECH After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Like Small Cap Stocks < $20?
You should, we just banked a 30% winner in 2 days!
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
MRNAModerna, Inc. -5.06%150.000.0%$678.53m
AMGNAmgen, Inc. -0.35%249.701.5%$585.90m
GILDGilead Sciences, Inc. -1.27%65.181.0%$429.55m
VRTXVertex Pharmaceuticals, Inc. -1.65%294.291.9%$402.50m
REGNRegeneron Pharmaceuticals, Inc. -1.81%624.832.6%$354.90m
ILMNIllumina, Inc. -1.86%209.063.3%$307.20m
SNSSSunesis Pharmaceuticals, Inc. 2.22%4.150.7%$290.10m
NVAXNovavax, Inc. -5.56%37.1875.7%$231.38m
BIIBBiogen, Inc. -0.57%216.341.8%$185.52m
BNTXBioNTech SE -2.91%147.610.0%$150.86m
SAVACassava Sciences, Inc. 2.92%26.470.0%$120.22m
GOVXGeoVax Labs, Inc. -12.83%1.970.0%$104.86m
BMRNBioMarin Pharmaceutical, Inc. -1.98%92.964.2%$97.95m
CRSPCRISPR Therapeutics AG 0.57%72.150.6%$91.12m
EXASEXACT Sciences Corp. -2.73%38.4817.6%$84.05m

Company Profile

Bio-Techne Corp. engages in the development, manufacture and sale of biotechnology reagents and instruments for the research and clinical diagnostic markets. It operates through the following segments: Protein Sciences and Diagnostics & Genomics. The Protein Sciences segment develops and manufactures purified proteins and reagent solutions most notably cytokines and growth factors, antibodies, immunoassays, biologically active small molecule compounds, tissue culture reagents and T-Cell activation technologies. This segment also includes protein analysis solutions that offer researchers efficient and streamlined options for automated western blot and multiplexed ELISA workflow. The Diagnostics & Genomics segment develops and manufactures diagnostic products, including FDA-regulated controls, calibrators, blood gas and clinical chemistry controls and other reagents for OEM and clinical customers, as well as a portfolio of clinical molecular diagnostic oncology assays, including the ExoDx Prostate (IntelliScore) test (EPI) for prostate cancer diagnosis. This segment also manufactures and sells advanced tissue-based in-situ hybridization assays (ISH) for research and clinical use. The company was founded in 1976 and is headquartered in Minneapolis, MN.